AstraZeneca, breast cancer
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
"Boy Meets World" star Danielle Fishel said she is finished with radiation treatment for cancer and opened up about the side ...
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
12h
Inside Edition' reporter Alison Hall undergoes a double mastectomy, after discovering her breast cancer while on assignment.
Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback